Research comparison
BPC-157 vs TB-500
BPC-157 and TB-500 are the two most-studied research peptides in connective-tissue and angiogenesis literature. Their mechanisms are complementary, not redundant — which is why preclinical protocols often run them together.
Short answer
BPC-157 and TB-500 are the two most-studied research peptides in connective-tissue and angiogenesis literature. Their mechanisms are complementary, not redundant — which is why preclinical protocols often run them together.
Research-context summary: For a single-variable connective-tissue or gastrointestinal-mucosa experiment, BPC-157 is the more directly relevant tool compound. For cardiomyocyte survival, cardiac progenitor reactivation, or actin-cytoskeleton-driven cell migration, TB-500 has the larger directly-relevant evidence base. For experiments that want to model both growth-factor and cytoskeletal arms of tissue remodelling, the combination is the most common protocol — and the reason HALO supplies a pre-blended research preparation in addition to the individual compounds.
Use limitation: HALO comparison pages are for research context only; both materials are RUO and not for human or veterinary use.
| BPC-157 | TB-500 | |
|---|---|---|
| Family | Synthetic pentadecapeptide derived from a gastric protein | Synthetic Thymosin β4 (Tβ4) actin-binding fragment analogue |
| CAS | 137525-51-0 | 77591-33-4 |
| Molecular weight | 1,419.56 g/mol | 4,963.5 g/mol |
| Primary mechanism | NO/eNOS/cGMP + VEGFR2 phosphorylation → ERK1/2, PI3K-Akt; EGR-1 transcription factor → PDGF/VEGF/FGF | G-actin sequestration → F-actin polymerisation balance; PINCH-ILK-α-Parvin → Akt survival signalling |
| Secondary signalling | Dopaminergic / serotonergic interactions in rodent brain; NF-κB modulation in intestinal models | HIF-1α hypoxia-response transcription target; VEGF and MMP upregulation in endothelial models |
| Primary research models | Tendon/ligament repair, gastric mucosa, vascular endothelial cultures, dopaminergic CNS models | Cardiac regeneration (post-MI), tendon repair, ischaemia-reperfusion, neural injury models |
| Available sizes (HALO) | 2 mg · 5 mg · 10 mg | 2 mg · 5 mg · 10 mg |
| Reconstitution | Sterile bacteriostatic water or validated research diluent; 1 mg/mL typical | Sterile bacteriostatic water or validated research diluent; 1–2 mg/mL typical |
| Storage | −20 °C lyophilized · 4 °C reconstituted ≤28 d | −20 °C lyophilized · 4 °C reconstituted ≤28 d |
Mechanism overlap and divergence
Both compounds support angiogenesis-related endpoints in research models, but through unrelated upstream mechanisms. BPC-157 acts on the endothelial NO synthase / VEGFR2 axis — increasing eNOS expression, NO-dependent vasodilation, and direct VEGFR2 phosphorylation that drives ERK1/2 and PI3K-Akt downstream. TB-500 acts on the cytoskeletal regulator side — sequestering G-actin to modulate F-actin polymerisation, and engaging the PINCH-ILK-α-Parvin complex to activate Akt survival signalling. The shared downstream node (Akt) makes them experimentally interesting in combination, but the upstream entry points are distinct.
Why researchers run them in combination
Pre-clinical tissue-model studies frequently use both peptides together precisely because the entry points do not overlap. BPC-157 provides angiogenic and growth-factor-axis signalling; TB-500 provides cytoskeletal regulation and survival signalling. The two signals converge on the same biological endpoint (controlled tissue remodelling) through independent pathways, which makes combination experiments useful for dissecting how much of an outcome depends on growth-factor signalling versus cytoskeletal dynamics. HALO supplies both compounds individually as well as a pre-combined research blend, depending on the protocol.
Choosing one for a single-variable experiment
If the research question is about tendon, ligament, or gastrointestinal mucosa, BPC-157 has the longer published literature in those specific contexts. If the question is about cardiomyocyte survival after ischaemia, cardiac progenitor reactivation, or actin-cytoskeleton-driven cell migration, TB-500 / Thymosin β4 has the larger and more directly relevant evidence base. For pure angiogenesis assays (endothelial migration, Matrigel tube formation), both have published activity — BPC-157 through VEGFR2 and TB-500 through HIF-1α/VEGF — and the choice depends on which upstream node the study wants to interrogate.
Identity, reconstitution, and storage
BPC-157 is a much smaller peptide (1,419.56 vs 4,963.5 g/mol) and dissolves in seconds. TB-500 also dissolves readily but is more sensitive to vigorous mechanical agitation due to its size — both should be reconstituted by gentle swirling rather than vortex mixing. Both ship lyophilized at ≥98% HPLC, both store at −20 °C dry and 4 °C in solution for up to 28 days. Aliquot to −80 °C for longer protocols and avoid freeze-thaw cycling.
Common comparison questions
Can BPC-157 and TB-500 be co-administered in research?
Which is better-studied in cardiac research?
Do BPC-157 and TB-500 share the same downstream signalling?
Which is more sensitive to reconstitution handling?
Research use only. Both compounds are sold by HALO for in vitro and qualified laboratory research only. Not for human or veterinary use, diagnosis, or treatment.